Skip to main content

Table 1 Summary and findings of neoadjuvant chemotherapy trials

From: American Society for Clinical Oncology 39thAnnual Meeting, Chicago, Illinois, USA, 31 May to 3 June 2003: Breast cancer neoadjuvant and adjuvant chemotherapy – prognostic and predictive markers

Abstract no. Treatment n pCR
1 Paclitaxel weekly and FAC 24 25% (breast and lymph nodes)
32 Docetaxel 100 mg/m2 q 3 weeks × 4 24 0%
33 Doxorubicin 75 mg/m2 × 3; then docetaxel 40 mg/m2 q week × 6 70 12.5%
34 Doxyfluoridine 800 mg/m2 D1-14; docetaxel 60 mg/m2 D8 q 3 weeks 20 14%
35 Paclitaxel doxorubicin standard or DD × 6 460 ER- 26%
    ER+ 8%
37 Paclitaxel + doxorubicin × 4 then CMF × 4 451 23%
80 Epirubicin 120 mg/m2 q 3 weeks ± tamoxifen 211 ER- 23.4%
    ER+ 4.6%
83 Vinorelbine 25 mg/m2 D1 + 8 and epirubicin 60 mg/m2 D1 versus AC × 6 411 15% both arms
85 TAC × 2: then PR to TAC × 6 (107 patients) 151 19%
  <PR to TAC × 4 (24 patients) or vinorelbine and xeloda × 4 (20 patients)   26% for clinical responders to TAC
86 Vinorelbine/herceptin 28 29%
    cCR+PR 93%
107 Epirubicin 60 mg/m2 D1, CDDP 60 mg/m2 D1, xeloda 1000 mg/m2 BD D1-14 48 27%
131 Docetaxel 60 mg/m2 + vinorelbine 45 mg/m2 q 2 weeks + GCSF + herceptin in HER2+ 33 36%
140 Gemcitabine 1 g/m2, epirubicin 90 mg/ m2, paclitaxel 175 mg/m2 q 3 weeks 22 22.7%
143 Docetaxel 100 mg/m2 q 3 weeks × 4 42 10%
160 Anthracycline SD or PD; 5FU 500 mg/m2/w + gemcitabine 100 mg/m2/w + dexamethasone 16 mg throughout radiotherapy (50 Gy +10 Gy boost) 47 28%
    MRD (+pN0) 23%
163 Docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2 × 4 q 3 weeks 37 8%
190 Docetaxel 100 mg/m2 q 3 weeks × 6 88 19.8%
  1. CMF, cyclophosphamide, methotrexate and fluorouracil; ER, oestrogen receptor; 5FU, 5-fluorouracil; FAC, 5-fluorouracil, doxorubicin and cyclophosphamide; GCSF, granulocyte colony-stimulating factor; pCR, complete pathological response; TAC, docetaxel, doxorubicin and cyclophosphamide; PR, partial response; <PR, less than a partial response; cCR, complete clinical response; CDDP, cisplatin; DD, dose dense; SD, stable disease; PD, progessive disease; MRD, minimal residual disease; +pNO, pathological node negative.